HOUSE_OVERSIGHT_024666.jpg
1.05 MB
Extraction Summary
0
People
4
Organizations
0
Locations
0
Events
0
Relationships
3
Quotes
Document Information
Type:
Investment report / market research
File Size:
1.05 MB
Summary
This document is page 30 of a 'Cannabis Investment Report' dated December 2017, produced by Ackrell Capital, LLC. It contains a table titled 'Representative Dosage Amounts' detailing THC and CBD dosages for various ailments (e.g., Anxiety, Cancer, Glaucoma) and a paragraph discussing the lack of thorough research on the medical benefits and side effects of cannabis. The document bears the stamp 'HOUSE_OVERSIGHT_024666', indicating it is part of a document production to the House Oversight Committee, likely related to a financial investigation.
Organizations (4)
| Name | Type | Context |
|---|---|---|
| Ackrell Capital, LLC | ||
| FINRA | ||
| SIPC | ||
| House Oversight Committee |
Key Quotes (3)
"Neither the potential medicinal benefits and therapeutic applications of cannabis consumption nor the negative side effects of cannabis use have been thoroughly researched by medical science."Source
HOUSE_OVERSIGHT_024666.jpg
Quote #1
"Short-term negative side effects are believed by some to include sensory distortion, panic, anxiety, poor coordination of movement..."Source
HOUSE_OVERSIGHT_024666.jpg
Quote #2
"There is also an ongoing debate about whether cannabis consumption may lead to the abuse of more harmful substances (the so-called 'gateway drug' debate)."Source
HOUSE_OVERSIGHT_024666.jpg
Quote #3
Full Extracted Text
Complete text extracted from the document (1,427 characters)
ACKRELL
CAPITAL
Cannabis Investment Report | December 2017
CAPITAL
Cannabis Investment Report | December 2017
Representative Dosage Amounts
Desired Effect or Ailment
Dosage
Dosage Ratio
(THC:CBD)
Dosage
Dosage Ratio
(THC:CBD)
“High”
10 mg THC
10:1 to 100:1
10 mg THC
10:1 to 100:1
Anxiety, depression, spasms
25 mg CBD
1:10
25 mg CBD
1:10
Cancer
25 mg CBD
1:1
25 mg CBD
1:1
Chronic pain
2.5–20 mg THC
10:1
2.5–20 mg THC
10:1
Epileptic seizures
200–300 mg CBD
1:5
200–300 mg CBD
1:5
Glaucoma
20–40 mg CBD
1:2 to 1:4
20–40 mg CBD
1:2 to 1:4
Increased appetite
2.5 mg THC
5:1
2.5 mg THC
5:1
Multiple sclerosis
2.5–120 mg THC
1:1
2.5–120 mg THC
1:1
Schizophrenia
40–1,280 mg CBD
1:4 to 1:128
40–1,280 mg CBD
1:4 to 1:128
Sleep disorders
40–160 mg CBD
1:4 to 1:16
40–160 mg CBD
1:4 to 1:16
Neither the potential medicinal benefits and therapeutic applications of cannabis consumption nor
the negative side effects of cannabis use have been thoroughly researched by medical science. Short-
term negative side effects are believed by some to include sensory distortion, panic, anxiety, poor coor-
dination of movement, reduced reaction time, lethargy or drowsiness, depression and elevated heart
rate. Longer-term effects may include suppression of the immune system, growth disorders, destruc-
tion of lung fibers, brain lesions, reduced sexual capacity, difficulties with concentration, reduced abil-
ity to learn and retain information, and personality and mood changes. There is also an ongoing debate
about whether cannabis consumption may lead to the abuse of more harmful substances (the so-called
“gateway drug” debate).
the negative side effects of cannabis use have been thoroughly researched by medical science. Short-
term negative side effects are believed by some to include sensory distortion, panic, anxiety, poor coor-
dination of movement, reduced reaction time, lethargy or drowsiness, depression and elevated heart
rate. Longer-term effects may include suppression of the immune system, growth disorders, destruc-
tion of lung fibers, brain lesions, reduced sexual capacity, difficulties with concentration, reduced abil-
ity to learn and retain information, and personality and mood changes. There is also an ongoing debate
about whether cannabis consumption may lead to the abuse of more harmful substances (the so-called
“gateway drug” debate).
30
© 2017 Ackrell Capital, LLC | Member FINRA / SIPC
© 2017 Ackrell Capital, LLC | Member FINRA / SIPC
HOUSE_OVERSIGHT_024666
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document